| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
|
Charehbili, A.
|
|
|
25 |
5 |
p. 998-1004
|
artikel
|
| 2 |
Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology
|
Hentrich, M.
|
|
|
25 |
5 |
p. 936-947
|
artikel
|
| 3 |
Cervical cancer screening: on the way to a shift from cytology to full molecular screening
|
Dijkstra, M.G.
|
|
|
25 |
5 |
p. 927-935
|
artikel
|
| 4 |
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial
|
Fizazi, K.
|
|
|
25 |
5 |
p. 987-991
|
artikel
|
| 5 |
Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology
|
Swanton, C.
|
|
|
25 |
5 |
p. 917-918
|
artikel
|
| 6 |
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma
|
Gupta, A.
|
|
|
25 |
5 |
p. 968-974
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
25 |
5 |
p. ii-iii
|
artikel
|
| 8 |
Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk
|
Lestuzzi, C.
|
|
|
25 |
5 |
p. 1059-1064
|
artikel
|
| 9 |
Gene expression and prognosis in bladder cancer—real progress? Editorial on ‘S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy’
|
Symanowski, J.T.
|
|
|
25 |
5 |
p. 919-920
|
artikel
|
| 10 |
Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study
|
Gandaglia, G.
|
|
|
25 |
5 |
p. 979-986
|
artikel
|
| 11 |
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
|
Barlesi, F.
|
|
|
25 |
5 |
p. 1044-1052
|
artikel
|
| 12 |
Medical oncology: in search of a definition
|
Numico, G.
|
|
|
25 |
5 |
p. 1075-1076
|
artikel
|
| 13 |
Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
|
Goldstein, J.
|
|
|
25 |
5 |
p. 1032-1038
|
artikel
|
| 14 |
Muscle dysfunction in cancer patients
|
Christensen, J.F.
|
|
|
25 |
5 |
p. 947-958
|
artikel
|
| 15 |
Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) †
|
Dietrich, S.
|
|
|
25 |
5 |
p. 1053-1058
|
artikel
|
| 16 |
Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB–IVA cervical cancer with or without immunomodulator Z-100: a JGOG study
|
Sugiyama, T.
|
|
|
25 |
5 |
p. 1011-1017
|
artikel
|
| 17 |
Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051) †
|
Lockhart, A.C.
|
|
|
25 |
5 |
p. 1039-1044
|
artikel
|
| 18 |
Prediagnostic transcriptomic markers of Chronic lymphocytic leukemia reveal perturbations 10 years before diagnosis
|
Chadeau-Hyam, M.
|
|
|
25 |
5 |
p. 1065-1072
|
artikel
|
| 19 |
Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab
|
Campiglio, M.
|
|
|
25 |
5 |
p. 1073-1074
|
artikel
|
| 20 |
S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy
|
Kim, W.T.
|
|
|
25 |
5 |
p. 974-979
|
artikel
|
| 21 |
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study
|
Sinn, M.
|
|
|
25 |
5 |
p. 1025-1032
|
artikel
|
| 22 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study) †
|
Folprecht, G.
|
|
|
25 |
5 |
p. 1018-1025
|
artikel
|
| 23 |
Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?
|
Adams, H.J.A.
|
|
|
25 |
5 |
p. 921-927
|
artikel
|
| 24 |
Table of Contents
|
|
|
|
25 |
5 |
p. iv-v
|
artikel
|
| 25 |
The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors
|
Cassier, P.A.
|
|
|
25 |
5 |
p. 1074-1075
|
artikel
|
| 26 |
Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy
|
Bane, A.L.
|
|
|
25 |
5 |
p. 992-998
|
artikel
|
| 27 |
Which threshold for ER positivity? a retrospective study based on 9639 patients
|
Yi, M.
|
|
|
25 |
5 |
p. 1004-1011
|
artikel
|
| 28 |
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
|
Turajlic, S.
|
|
|
25 |
5 |
p. 959-967
|
artikel
|
Tijdschrift beschrijving